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In the menstrual cycle, the mid-cycle surge of gonadotropins (both luteinising hormone [LH] and follicle-stimulating
hormone [FSH]) signals the initiation of the periovulatory interval, during which the follicle augments progesterone
production and begins to luteinise, ultimately leading to the rupture of the follicle wall and the release of an oocyte.
The administration of gonadotropins in controlled ovarian stimulation (COS) leads to supraphysiological steroid
concentrations of a very different profile compared with those seen during natural cycles. It has been suggested
that these high steroid concentrations cause alterations in endometrial development, affecting oocyte viability in
assisted reproductive technology. Furthermore, it has been proposed that elevated progesterone levels have a
negative effect on the reproductive outcome of COS. This may arise from an asynchrony between embryo stage
and endometrium status at the window of implantation. The regulation of progesterone production by the developing
follicles during COS is a complicated interplay of hormonal systems involving the theca and granulosa cells, and the effect
of the actions of both LH and FSH. The present paper reviews current knowledge of the regulation of progesterone in
the human ovary during the follicular phase and highlights areas where knowledge remains limited. In this review, we
provide in-depth information outlining the regulation and function of gonadotropins in the complicated area of
steroidogenesis. Based on current evidence, it is not clear whether the high levels of progesterone produced
during COS have detrimental effects on fertility.
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Controlled ovarian stimulation (COS) is an important
component of assisted reproductive technology (ART).
Following exogenous gonadotropin administration, COS
leads to the development of multiple ovarian follicles. It
has been suggested that due to endocrine effects on the
endometrium COS may have a deleterious effect on the
window of implantation during in vitro fertilisation (IVF)
cycles. Based on post-ovulation histological assessments,
Bourgain and Devroey [1] suggested that COS is associ-
ated with ‘advancement of endometrial development’.
More recent studies have also shown differences in gene
expression; however, the differences suggest that endometrial* Correspondence: diego.ezcurra@emdserono.com
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article, unless otherwise stated.development is delayed by COS, and that this has clinical
implications [2]. Although the clinical significance of these
effects is still not clearly defined, and may involve only a
relatively small proportion of patients, it is important to
determine whether endometrial development is affected
by the supraphysiological levels of steroids produced by
multiple preovulatory follicles as a result of COS. It is also
important to determine the precise nature of the milieu of
circulating steroids that are present during COS.
This review provides details on the complex area of hu-
man ovarian steroidogenesis during the follicular phase at
the molecular, functional and clinical level, and provides
evidence to address the question of whether high proges-
terone levels produced during the late follicular phase
have an effect on pregnancy outcomes following COS.d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Gonadotropins in steroidogenesis
The development of human ovarian follicles depends on
the sequential effects of the two principal gonadotropins,
follicle-stimulating hormone (FSH) and luteinising hor-
mone (LH). FSH acts on early antral follicles to stimulate
growth (cell division), steroidogenesis, and the expression
of LH receptors. Subsequently, LH, in synergy with FSH,
acts on the FSH-stimulated follicle to maintain growth,
and is eventually responsible for the processes of luteinisa-
tion and ovulation. In the normal cycle, the dominant
follicle maintains its growth and hormone output in the
face of declining FSH concentrations by the acquisition
of increased sensitivity to LH [3,4]. Through the follicular
stage, FSH and LH both stimulate cyclic adenosine
monophosphate (cAMP) production and elicit growth and
oestrogen secretion through this same mechanism [5,6].
The implementation of COS using exogenous gonado-
tropins leads to supraphysiological levels of circulating FSH
throughout the follicular phase. These levels are higher and
of a very different pattern compared with that seen during
the normal menstrual cycle [7,8].
Activation of LH and FSH receptors on granulosa cells
leads to the activation of most known intracellular signal-
ling pathways, i.e. the adenylate cyclase, protein kinase C
(inositol phosphate), the mitogen-activated protein (MAP)
kinase, and extracellular signal-regulated kinase pathways
[5]. In human theca cells, signalling pathways are un-
known; however, data from studies with bovine theca cells
indicate that LH-induced Akt phosphorylation is modu-
lated via the MAP kinase signalling pathway [9]. FSH-
induced granulosa cell differentiation also leads to induc-
tion of LH receptor expression, increased steroidogenesis,
and induction of various transforming growth factor beta
(TGF-b)-related growth factors. While this is reasonably
well understood in natural cycles of laboratory animals
and, partially, in humans, less is known about how these
processes are affected by the supraphysiological concen-
trations of FSH used in COS, and how this might in turn
affect oocyte viability in ART.
Modification of responsiveness of granulosa cells to LH
In the normal cycle the dominant follicle continues to
grow in the environment of falling FSH concentrations
by promoting its sensitivity to gonadotrophins. This in-
cludes the establishment of granulosa-cell sensitivity to
LH. The granulosa cells in small antral follicles show lit-
tle sensitivity to LH; however, as they grow, the granu-
losa cells become highly sensitive to LH and in humans
the sensitivity towards FSH becomes reduced [4]. It is
through this mechanism that luteinisation takes place in
response to the LH surge.
Activation of the LH receptor in granulosa cells leads
to the transcription and protein production of two keyenzymes of steroidogenesis: cholesterol side-chain cleav-
age (P450scc) and aromatase (P450arom). In a study by
Yong et al. granulosa cells removed from follicles prior
to the LH surge were differentially dependent upon fol-
licular size, and both FSH and LH strongly stimulated
P450arom mRNA expression and estradiol production
in mature rat granulosa cells. The study also showed that
P450scc mRNA expression and progesterone biosyn-
thesis were maximal only in the presence of both FSH
and LH [10].
It is likely, therefore, that as follicles mature the role of
LH in steroid biosynthesis becomes more important.
Not only is LH required for supply of the androgen sub-
strate for aromatase, it is also important in the regula-
tion of the aromatase enzyme itself.
The steroidogenic pathway
The critical step in steroidogenesis is the initial con-
version of cholesterol (a carbon27 [C27] steroid) to
pregnenolone (the primary C21 product), from which
all other steroids are generated (Figure 1) [11,12]. The
cholesterol side-chain cleavage cytochrome P450 enzyme
(P450scc), encoded by the CYP11A gene, catalyses this
step and is considered to be the rate-limiting step in
steroidogenesis.
Following initial cleavage, the resulting pregnenolone
is metabolised in one of three pathways, two of which are
illustrated in Figure 1, representing those seen in the ovary.
One route of metabolism is via the D5 pathway (Figure 1,
red arrows); the first two steps are effected by the same en-
zyme, CYP17 (P45017a), enzyme complex, which exhibits
both hydroxylase and lyase activity (the third pathway
for pregnenolone metabolism, the adrenal system, is not
reviewed in this article). Hydroxylation of pregnenolone
at the C17a position yields 17-hydroxypregnenolone,
and subsequent removal of the acetyl group forms the
androgen precursor dehydroepiandrosterone (DHEA). Im-
portantly, CYP17 is located exclusively in thecal/interstitial
cells (i.e. the extrafollicular compartment of the ovary)
[13], whereas CYP19 (aromatase) is expressed only in
the granulosa cells (i.e. the intrafollicular compartment)
[14]. Thus, the theca cells provide the androgens re-
quired by the developing follicles for conversion into
oestrogens by the granulosa cells [15].
In the ovary, the second route of metabolism for preg-
nenolone metabolism (Figure 1, blue arrows) begins with
the conversion of pregnenolone to progesterone by the
action of 3β-HSD. This conversion is essentially irre-
versible, as are all the dehydrogenase reactions cata-
lysed by 3β-HSD. Progesterone can then be converted
to 17-hydroxyprogesterone by CYP17 (the D4 pathway).
In humans, however, 17-hydroxyprogesterone cannot be
further metabolised [8]. CYP17 exhibits marked species
differences, particularly with respect to the lyase reaction.
Figure 1 Human ovarian steroidogenesis. Dashed arrows show the route of pregnenolone metabolism via the Δ5 pathway. Solid arrows show
an alternative route of pregnenolone metabolism beginning with the conversion of pregnenolone to progesterone by the action of 3β-HSD.
Adapted from Wickenheisser JK, et al. 2006 [12].
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are both substrates for rodent and guinea-pig CYP17,
while the bovine enzyme shows some selectivity for 17-
hydroxyprogesterone, but human CYP17 acts on 17-
hydroxypregnenolone almost exclusively. In humans,
very little 17-hydroxyprogesterone is converted to
androstenedione. Thus, in humans, progesterone and/
or 17-hydroxyprogesterone produced by the granulosa
cells are the end products of the D4 pathway; the only
route for estradiol synthesis in the human ovary is via
the D5 pathway. One role of 17-hydroxyprogesterone
may be to modulate the biological activity of cortisol,
thereby reducing the inflammatory-like reactions associ-
ated with ovulation [16]. It would be of interest to know
whether there are any conditions in which the substrate
specificity of human CYP17 is altered such that the en-
zyme is able to process 17-hydroxyprogesterone.
Overall, the product of cholesterol side-chain cleavage,
pregnenolone (C21), has two further routes of metabolism
in the ovary: via the D4 pathway to progesterone (also
C21) and the D5 pathway to 17aOH pregnenolone, with
further side-chain cleavage to the C19 androgens.
In the context of COS, it is important to consider
whether the process of steroidogenesis remains the
same during stimulated and natural cycles, and to de-
termine which components of the system could beaffected by the supraphysiological concentrations of
gonadotropins achieved during COS.
CYP17 activity
Role of CYP17 in the regulation of adrenal
steroidogenesis CYP17 is also known to have a crucial
role in determining the class of steroid produced in human
adrenal steroidogenesis. Thus, in the zona glomerulosa,
CYP17 is absent, which means that C21 deoxy steroids are
produced, the main final product being the mineralocortic-
oid aldosterone. In the zona fasciculata, where CYP17
hydroxylase activity is present but lyase is absent, C21
17-hydroxy steroids are produced, which means that
the main product is the glucocorticoid cortisol. Where
both hydroxylase and lyase activity are present (in the
zona reticularis), the androgen precursor DHEA is pro-
duced in large amounts [11].
The implication of this analysis is that it demonstrates
that CYP17 activity can have a major influence on the
end products of steroidogenesis.
Regulation of CYP17 in theca cells The hydroxylase
and lyase activity of CYP17 are located at the same ac-
tive site on the enzyme, but the discrimination between
the two is regulated post-translationally [11]. Similar to
all other microsomal forms of cytochrome P450, CYP17
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reduced nicotinamide adenine dinucleotide phosphate
(NADP) [17]. This activity is promoted by serine phos-
phorylation of CYP17 and the allosteric effect of cyto-
chrome b5, both of which optimise the interaction of
CYP17 with its obligatory electron donor, P450 oxido-
reductase (POR) [17,18]. Increasing the ratio of POR
to CYP17 also increases the ratio of lyase to hydroxy-
lase activity [11].
In mature female rats, recombinant human FSH
(rhFSH) was shown to induce ovarian CYP17 messenger
RNA (mRNA) expression of thecal cells (Figure 2, first
panel) [13]. In immature females, expression of CYP17
mRNA was undetectable in the absence of endogenous
FSH, and rhFSH induced marked expression of CYP17
mRNA in the theca – but not granulosa – cells (Figure 2,
second panel) [13]. Therefore, although FSH receptors are
expressed only on granulosa cells and CYP17 only on
theca calls, FSH appears to be an important regulator of
CYP17.Other factors affecting CYP17 activity Insulin and
insulin-like growth factor (IGF)-1 and -2 have been shown
to stimulate androstenedione production by human theca
cells in vitro, and inhibin, which is induced by FSH and
produced only in the granulosa cells, also induces thecal
androgen synthesis [19]. The effect of inhibin is thought
to represent an FSH-driven paracrine signal from the
granulosa to the theca cells, affecting either the expression
or the activity of CYP17, and thereby increasing androgen
production. The effect of inhibin and IGF on androgen
production is further enhanced by the addition of the ac-
tion of LH on thecal cells [19].Figure 2 The effect of r-hFSH administration in vivo on ovarian P450c
pregnant mare serum gonadotropin; FSH: follicule stimulating hormone; GrA number of other factors have been shown to inhibit
17-hydroxypregnenolone, DHEA and androgen production
by theca cells (i.e. CYP17 activity). These include epidermal
growth factor (EGF), fibroblast growth factor (FGF),
TGF-b, growth differentiation factor-9 and activin
[8,20-23]. The relevance of these various factors to the
effects of FSH and LH on the steroid output of the fol-
licle is yet to be determined.
Potential implications of CYP17 regulation for COS
It is not currently understood how the regulation of
CYP17 enzyme activity in human theca cells is affected
during COS, and whether this alters steroidogenesis
compared with the normal menstrual cycle. It is possible
that, for example, changes in CYP17 activity could affect
the relative contribution of theca and granulosa cells to
progesterone production. It seems likely that changes in
CYP17 activity would affect the types of steroids pro-
duced by the theca cells because, as metabolism of preg-
nenolone via the D5 pathway to estradiol increased, so
progesterone production would be expected to be re-
duced due to depletion of pregnenolone substrate for
3β-HSD. Currently, however, it is not known what pro-
portion of the progesterone produced during the follicu-
lar phase is contributed by the theca and granulosa cells.
Indeed, it is likely that the proportion of granulosa cell-
derived progesterone will evolve as the follicle grows
and the granulosa cells become more sensitive to LH.
Given that CYP17 expression can be enhanced both by
stimulation with LH and through paracrine mechanisms
from the follicle (inhibin, via FSH), profound induction
of CYP17 during COS may lead to a change in the sub-
strate preference of the enzyme, or may be affected by
an abundance of 17-hydroxyprogesterone.17α mRNA expression in rats. FSH values are IU/mL. PMSG:
: granulosa; Th: theca. Adapted from Smyth CD, et al. 1993 [13].
Figure 3 The follicle as a factory of steroid biosynthesis. During
controlled ovarian stimulation, there is a continuum of follicular
development. Source: http://en.wikipedia.org/wiki/Ovarian_follicle
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CYP11A The first step in the process of steroidogenesis,
the conversion of cholesterol to pregnenolone, is trad-
itionally considered to be rate-limiting [11] for all further
steroid metabolism. Chronic regulation is principally at the
level of transcription of the gene for CYP11A (P450scc),
the enzyme responsible for catalysing the conversion.
Acute regulation is mediated by steroid acute regulatory
protein (StAR), which facilitates the influx of cholesterol
into the mitochondria, where the CYP11A enzyme is
located. StAR expression is enhanced by cAMP and by
stimulation of the granulosa cells with FSH and LH/
human chorionic gonadotropin (hCG).
3β-HSD The dehydrogenase enzyme 3β-HSD is respon-
sible for catalysing the conversion of D5 steroids to the
D4 configuration (Figure 1), and is therefore essential
for the biosynthesis of all classes of steroid hormones.
The expression of 3β-HSD has an important role in both
theca and granulosa cells. The relative levels of activity
of 3β-HSD and CYP17 determine whether pregnenolone
is metabolised primarily via the D5 pathway (leading to
estrogen production) or the D4 pathway (leading to pro-
gesterone and 17-hydroxyprogesterone).
In cultured granulosa cells from immature rats, FSH
was shown to increase 3β-HSD mRNA, protein and en-
zyme activity [24,25]. hCG/LH has also been shown to
increase 3β-HSD expression in human ovarian theca
cells [26]. Thus, although 3β-HSD expression appears
to be highly constitutive, it can be augmented by both
FSH in the granulosa cells and LH in the theca cells.
Currently it is not known to what extent the activity of
the enzyme can be up-regulated, or whether gonado-
tropins have differential effects on 3β-HSD activity in
theca and granulosa cells, where such effects could
have a major impact on follicular steroid output.
Human follicular fluid steroids
Analyses of steroid concentrations in human follicular
fluids during the normal follicular phase appear to re-
flect this level of understanding of enzyme activity, and
the interplay between the two cell types. It has been
clearly demonstrated that high concentrations of andro-
gens are universal in human follicles, indicating that thecal
cell activity is intrinsic to steroidogenesis at all stages, irre-
spective of the source of progesterone. Furthermore, as
follicles grow there is a general tendency for the relative
proportion of steroids to evolve. The general pattern indi-
cates that small follicles (FD <6 mm) are “androgenic” and
larger follicles are “estrogenic” and highly “progestogenic”
in pre-ovulatory follicles. The shift from the estrogenic
state to the progestogenic state does not involve a re-
duction in the estrogen component, rather an increase
in progesterone concentrations. This shift is consistentwith both increased steroidogenesis by, and increased
LH sensitivity of, granulosa cells [27].
Source of progesterone during the follicular phase of COS
and the implications for successful embryo implantation
Several studies have reported raised concentrations of
progesterone in the late follicular phase of gonadotropin-
releasing hormone (GnRH)-agonist and antagonist con-
trolled COS (i.e. in the apparent absence of raised LH).
There is continued debate regarding the clinical signifi-
cance of these relatively modest concentration changes. It
has been hypothesised that increases in circulating proges-
terone concentrations from non-luteinised tissues may
lead to advances in the development of the endometrium
and effectively reduce the window of implantation. As a
result, excessive asynchrony between the development of
the egg and the embryo, timed by the hCG or LH surge,
and that of the endometrium, influenced by prematurely
raised progesterone, would be likely to reduce implant-
ation rates [28]. The concentration of progesterone that
would be expected to have effects on the endometrium is
likely to approximate that seen on the day after the LH
surge during the follicular phase of a natural cycle. How-
ever, there is no reason to believe that elevated circulating
progesterone affects the development of the egg or em-
bryo, as the concentrations seen in each follicular fluid are
many times higher than that seen in the circulation.
It is critical to recognise that during COS, there is a
continuum of follicular development (Figure 3). At any
given timepoint, there will be a number of follicles at
different stages of development – at least in young
women with many growing follicles. Hormone concen-
trations measured in the peripheral circulation therefore
depend on the contribution of multiple small, medium
and large follicles. While the conversion of cholesterol is
the rate-limiting step in steroidogenesis, during the fol-
licular phase, the LH drive for androgen biosynthesis in
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the follicle.
Local and systemic progesterone concentrations during
normal cycles and in COS
The intrafollicular concentration of progesterone of women
during the normal menstrual cycle was described by
Schneyer and colleagues [29] who showed clearly the re-
lationship between the production of progesterone and
follicle diameter and the number of days before ovula-
tion (Figure 4). Progesterone was detectable even in the
smallest follicles and increased linearly with both follicle
size (r = 0.83; p <0.0001) and maturity (r = 0.77; p <0.0001).
During the early follicular phase of a normal cycle,
studies measuring steroid levels in ovarian veins showed
that the estradiol concentration in veins draining the ac-
tive follicles is already twice the maximum of that in the
peripheral circulation; further increases are apparent by
the mid-follicular phase [30]. Raised levels of progester-
one can also be detected during the early follicular
phase, while the follicles are still very small (10–12mm);
by the mid-follicular phase, the progesterone concentra-
tion in the active veins is profoundly increased com-
pared with the peripheral circulation [30]. Clearly, there
is a tremendous output of progesterone by the developing
follicle during normal cycles. While some of this enters
the peripheral circulation, most seems to be metabolised
by the liver such that peripheral concentrations are not in-
creased prior to luteinisation.
During COS, the fact that multiple follicles are con-
tributing to the steroid mix from both ovaries, proges-
terone output is likely to increase the progesterone level
in the periphery. Exogenous FSH acting on the granu-
losa cells would be likely to increase circulating proges-
terone, whereas it is unclear whether LH drives theFigure 4 Intrafollicular concentrations of progesterone in relation to
the natural menstrual cycle. Filled circles show the dominant follicles and
AL et al. 2000 [29].theca cells to produce androgens at the expense of pro-
gesterone. A positive correlation between LH surge and
progesterone release has been reported [31].
However, in the early follicular phase, the granulosa
cells do not respond well to low LH activity, and increases
in LH (e.g. flare start) have been shown to increase pro-
gesterone output from what is considered to be the old
corpus luteum. In a study by Cedrin-Durnerin, early in-
creases of progesterone in response to LH increases were
prevented in women who were pretreated with a proges-
togen (norethisterone) [32].
An analysis by Ubaldi et al. assessed whether prema-
ture luteinisation could occur in GnRH agonist and FSH
(recombinant FSH and human urinary FSH) IVF cycles
and whether premature luteinisation affected IVF and
clinical outcome. Data indicated a positive correlation
between FSH and progesterone levels, in that area under
the FSH and progesterone curves were higher in cycles
with premature luteinisation. Area under the FSH curve
also correlated with the area under the progesterone
curve, suggesting that increased FSH-induced LH recep-
tivity in granulosa cells may be a factor in inducing pre-
mature luteinisation [33]. In a study by Beckers et al. in
which investigators assessed luteal phase LH and proges-
terone concentrations without corpus luteum exogenous
support, data also indicated concomitant increases in
progesterone levels as FSH levels increased [34].
In the MERIT (menotropin versus recombinant FSH
in-vitro fertilisation trial) study, where patients were
undergoing a GnRH agonist long protocol, serum and
follicular fluid progesterone concentrations were higher
among those who received recombinant FSH (rFSH:
GONAL-F) versus those treated with highly purified-
hMG (MENOPUR). In contrast, the follicular fluid con-
centrations of androgens and oestrogen were higher infollicular development in women during the follicular phase of
open circles show the non-dominant follicles. Adapted from Schneyer
Figure 5 Levels of progesterone and 17-OH-progesterone
during the follicular phase in women stimulated with different
doses of hCG. Shaded bars represent stimulation day 0, day 6 and
day of hCG triggering. Graph drawn using data from Thuesen et al.
2013 [40]. hCG: human chorionic gonadotropin.
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trations of progesterone were also related to the pres-
ence of a large follicular mass in patients treated with
r-hFSH [35]. In a separate sub-analysis of MERIT, ele-
vated circulating progesterone during the late follicular
phase (>4nmol/L on the day of hCG administration) was
associated with an increased ovarian response (egg yield)
in both treatment groups [36]. The above data suggest
that the higher incidence of elevated progesterone in the
rFSH group was consistent with findings in this sub-
group of a higher ovarian response, leading to more fol-
licles collectively containing a higher mass of granulosa
cells, a lower conversion of progesterone to androgens
in the r-hFSH group (due to the lack of LH/hCG in
rhFSH) and a modified endometrial receptivity due to
advancement of endometrial development. The authors
proposed a new and inexistent steroidogenic pathway in
which the hCG contained in hMG can convert intrafolli-
cular progesterone back to oestradiol.
Data from another study show that during treatment
with a GnRH antagonist, a large reduction in circulating
LH occurs for a short period of time (with no change in
circulating FSH because exogenous FSH is administered),
and that estradiol and progesterone concentrations are
highly correlated with the level of LH [37].
A further study of IVF/intracytoplasmic sperm injec-
tion (ICSI) patients using GnRH analogues for pituitary
down-regulation [38] reported that elevated progester-
one on the day of hCG administration was associated
with a lower ongoing pregnancy rate. Patients with lower
progesterone levels (≤1.5ng/mL) had significantly higher
ongoing pregnancy rates than those with higher levels,
irrespective of the GnRH analogue used for pituitary
down-regulation. Achieving a higher ovarian response,
as indicated by circulating oestradiol, appeared to be ad-
vantageous, in terms of achieving a higher ongoing preg-
nancy rate, only if progesterone was not elevated [38]. A
well-conducted study by Thuesen et al. [39] sought to
determine the optimal dose of hCG that would be com-
patible with good live birth rates. The authors examined
serum progesterone levels in women treated with hCG
at doses up to 150 IU from day 1 in combination with a
fixed dose of 150 IU r-hFSH. A positive dose response in
circulating progesterone was observed in this study but
concentrations were considered to be below that at which
impairment in the endometrium has been observed [39].
A later paper by the same group showed that the concen-
tration of 17-OH progesterone in the late follicular phase
of COS is much higher than that of progesterone. 17-OH
progesterone does also act via the progesterone receptor
and appears to be a more sensitive marker of premature
increases in “progestin” activity than progesterone itself
[40]. It is also possible that the relative concentration of
progesterone and 17-OH progesterone in the follicularand luteal phase respectively is an important measure of
progestin activity. In pre-ovulatory follicles there appears
to be approximately four times more progesterone than
17-OH progesterone, while the study by Thuesen et al
[40] showed that, in contrast, in the circulation, there is
far more 17-OH progesterone than progesterone (Figure 5).
This may be due to the conversion of progesterone to
17-OH progesterone upon leaving the follicle and pass-
ing through the theca cell layer. In the luteal phase there
appear to be more equal concentrations of progesterone
and 17-OH progesterone, but in this phase the secretion
is directly into the bloodstream where progesterone is not
readily converted to 17-OH progesterone.
The effect of elevated progesterone on pregnancy rates
may be treatment dependent. A large multicentre ran-
domised controlled trial of hMG versus rFSH in 749
women reported that in the rFSH group, women with
progesterone levels >4nmol/L had a significantly ongoing
lower pregnancy rate compared with those women with
progesterone levels ≤4nmol/L. While in the hMG group,
ongoing pregnancy rates were similar in women with
progesterone levels ≤4nmol/L or >4 nmol/L [41]. How-
ever, a recent study comparing progesterone response
to either r-hFSH/r-hLH or HP-hMG + urinary FSH re-
ported that serum and intra-follicular progesterone
levels and pregnancy rates were not significantly differ-
ent between groups [42].
The elevation in progesterone following COS may also
differ between low- and high-responder patients. In a
study by Fatemi et al. [43] of women receiving either
corifollitropin-α (an FSH agonist) or r-hFSH, elevated
progesterone (>1.5 ng/ml) was observed more frequently
in the high-responder groups in both treatment arms.
However, this study concluded that a high ovarian re-
sponse did not compromise ongoing pregnancy rates
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and frozen-thawed embryo transfer in patients treated
with corifollitropin-α or rFSH [43]. A further study
showed no detrimental effect of elevated progesterone in
the late follicular phase of high-responder patients, but
did observe an effect in low-responder patients [44]. This
suggests that when a few follicles are stimulated to pro-
duce large amounts of progesterone this may compromise
embryo quality rather than the endometrial receptivity
and that the endometrium cannot distinguish between
progesterone produced by a few or a large number of folli-
cles. However, the lower pregnancy rates may reflect other
reasons for the lower chance of becoming pregnant in
these low-responder patients.
The Nordic LH Study Group conducted an analysis of
progesterone measurements using archived blood samples
from 526 women in a randomised, controlled trial that
assessed rFSH+ rLH (n = 265) versus rFSH alone (n = 261)
in an agonist down-regulation long protocol for IVF/ICSI.
The rFSH starting dose was 150 or 225 IU/day, respect-
ively, in patients ≤35 and >35 years of age [45]. There were
no significant differences between treatment groups with
regard to oocyte retrieval, embryo transfer, implantation
and ongoing clinical pregnancy rates. Circulating levels
of LH were down-regulated on Days 1 and 6, and on the
day of hCG administration, LH was significantly higher
(p <0.001) in the rFSH + rLH group compared with the
rFSH group [45]. Progesterone levels on Day 1 and on the
day of ovulation induction were very similar between the
treatment groups, and the progesterone concentration on
the day of ovulation induction was significantly correlated
with the number of oocytes retrieved and the number of
follicles, but not with FSH consumption [46]. The level of
LH on the day of ovulation induction was significantly
correlated with the circulating progesterone level, but not
with the number of oocytes. There was no significant rela-
tionship between biochemical or clinical pregnancy rates
(per patient and per embryo transfer) and late follicular
phase serum progesterone levels. In fact, the group of pa-
tients with very high progesterone levels (≥7nmol/L) had
higher pregnancy rates than most of the other subgroups
[46]. Of interest, a study examining the administration of
DHEA in a woman with low ovarian reserve transplanted
with cryopreserved ovarian tissue [47] showed an immedi-
ate augmentation of her progesterone levels. This suggests
that the adrenal production of progesterone is important,
especially with regard to low progesterone levels observed
in the late follicular phase of the menstrual cycle.
These results indicate that the concentration of pro-
gesterone during the late follicular phase reflects the
number of preovulatory follicles and oocytes retrieved,
and that high circulating progesterone, may not have a
deleterious effect on pregnancy outcomes. When looking
at women in the early follicular phase, data also indicatea strong significant positive correlation between LH surge
and progesterone release [31]. In vitro studies bovine fol-
licular and luteal cells clearly showed that the higher the
level of LH activity, the higher the production of proges-
terone [48].
It is important to note that commercial laboratory as-
says to measure progesterone levels were developed for
use during the luteal phase (i.e. to determine whether or
not a patient has ovulated), requiring a 5–10 fold higher
sensitivity to progesterone levels than that which would
occur during the follicular phase [49-51]. Therefore current
assays that are used to test progesterone in the follicular
phase of COS may yield imprecise values. Further, accord-
ing to results of a survey of automated immunoassay ana-
lysers in Belgium, progesterone test results generally
showed high inter-laboratory coefficients of variation
(6–45%) and bias values. Investigators concluded that a
linear relationship between the reference value and re-
ported values was not assured for most testing methods
from 0.56 to 117.85 nmol/L of progesterone [52].
Conclusions
In this review, it has been shown that there is conflicting
evidence on the effects of high progesterone levels
(≥7 nmol/L) during the late follicular phase and the im-
pact that this has on the establishment of pregnancy. In
natural cycles, the concentration of progesterone in the
follicular fluid at the time of the LH surge is very high
compared with that of oestradiol [53], which indicates that
high levels of progesterone may be a natural event at this
time of the cycle. This demonstrates that high levels of
progesterone are aligned with normal ovarian physiology,
with high progesterone levels being required for the devel-
opment of the follicle. The timing of the increase in proges-
terone levels is important for endometrial development,
however, the final impact at the endometrial levels still
needs to be clarified.
LH and FSH activity are important drivers of oestradiol,
progesterone and androstenedione concentrations. During
COS, increased progesterone is related to the increased
number of follicles and thereby the total number of granu-
losa cells, and increased sensitivity to lower levels of LH,
thus an increase in LH may induce a further limited in-
crease in intrafollicular progesterone. In COS, the level of
steroidogenesis per cell or per follicle does not increase,
but total steroid production increases, in line with the in-
crease in the number of growing follicles and cells.
In this article we have shown that cholesterol is the
precursor for biosynthesis of steroids. Following the ini-
tial cleavage of cholesterol, the resulting pregnenolone
molecule can be metabolised by either the D4 or D5
pathway. In the D4 pathway, the metabolism of pregnen-
olone to progesterone by 3β-HSD is an irreversible reac-
tion, and progesterone can only be further metabolised
Figure 6 Gonadotropic regulation of steroidogenesis at different phases of the ovarian cycle. A summary of understanding based on the
currently available literature reviewed in this article. FSH: follicule stimulating hormone; hCG: human chorionic gonadotropin; LH: luteinising hormone.
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http://www.rbej.com/content/12/1/128to 17-hydroxyprogesterone. In the human ovary the only
way to produce oestradiol is via the D5 pathway, where
17-hydroxypregnenolone can undergo further side-chain
cleavage and modification. It is not currently known
how the pathway that pregnenolone follows is deter-
mined or why 17-hydroxyprogesterone is the final prod-
uct of the D4 pathway. It is also not currently known
whether conversion of 17-hydroxypregnenolone to 17-
hydroxyprogesterone or androstenedione is regulated
differently in follicles of different sizes. Furthermore, it
is important to understand how the regulation of CYP17enzyme activity in human theca cells is affected during
COS, and whether this alters steroidogenesis compared
with the normal menstrual cycle.
Based on the above evidence, it is not clear if the high
levels of progesterone produced during COS have detri-
mental effects on fertility outcomes. High doses of FSH
could be related to a reduced endometrial proliferation
through direct or indirect actions. The MERIT and
Nordic studies used high and low doses of FSH for the
same population of patients, however, the studies show
different results in relation to the high levels of
Andersen and Ezcurra Reproductive Biology and Endocrinology 2014, 12:128 Page 10 of 11
http://www.rbej.com/content/12/1/128progesterone and pregnancy outcomes [35,45]. Based on
this evidence it is possible that the differences are a re-
flection of FSH, progesterone or the combination of
both acting at the endometrial level. Our current under-
standing of the regulation of steroidogenesis by gonado-
tropins at different stages of the ovarian cycle is outlined
in Figure 6. However, unanswered questions remain and
further research in this area is required to help elucidate
the complex process of steroidogenesis and determine
the future implications for COS.
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